With current policy movement toward testing all patients with breast, ovarian, pancreatic, and prostate cancer for germline mutations driven by advances in treatment with PARP inhibitors or other targeted therapies, there is a need to develop and evaluate innovative delivery models for genetic testing for BRCA1 and BRCA2 and other targeted mutations. The gene discussed is BRCA1; the disease is Familial prostate cancer.